A phase i study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma

Andrea Wang-Gillam, Stacey Plambeck-Suess, Peter Goedegebuure, Peter O. Simon, Jonathan B. Mitchem, John R. Hornick, Steven Sorscher, Joel Picus, Rama Suresh, Albert C. Lockhart, Benjamin Tan, Williams G. Hawkins

Research output: Contribution to journalArticlepeer-review

54 Scopus citations

Abstract

Purpose This phase I study was conducted to determine the safety profile and maximum tolerated dose (MTD) of IMP321, a soluble lymphocyte activation gene-3 (LAG-3) Ig fusion protein and MHC Class II agonist, combined with gemcitabine in patients with advanced pancreatic adenocarcinoma. Patients and methods Patients with advanced pancreatic adenocarcinoma were treated with gemcitabine (1,000 mg/m2)(level 1), gemcitabine (1,000 mg/m 2) plus IMP 321 at 0.5 mg (level 2) and 2.0 mg (level 3), respectively. Safety, toxicity, and immunological markers at baseline and post treatment were assessed. Results A total of 18 patients were enrolled to the study, and 17 were evaluable for toxicity. None of the 6 patients who received 0.5 mg IMP321 experienced IMP321-related adverse events. Of the 5 patients who received IMP321 at the 2 mg dose level, 1 experienced rash, 1 reported hot flashes and 2 had mild pain at the injection sites. No severe adverse events previously attributed to IMP321 were observed. No significant differences were observed when comparing pre- and post-treatment levels of monocytes (CD11b+CD14+), conventional dendritic cells (CD11c+) or T cell subsets (CD4, CD8). Conclusions IMP321 in combination with gemcitabine is a well-tolerated regimen. IMP321 did not result in any severe adverse events. No incremental activity observed for the additional IMP 321 to gemcitabine at the dose levels evaluated, likely due to sub-optimal dosing. Immunological markers suggested that higher dose levels of IMP321 are needed for future clinical studies.

Original languageEnglish (US)
Pages (from-to)707-713
Number of pages7
JournalInvestigational New Drugs
Volume31
Issue number3
DOIs
StatePublished - Jun 2013
Externally publishedYes

Keywords

  • Chemo-immunotherapy
  • Front-line therapy
  • IMP321
  • LAG-3
  • Pancreatic adenocarcinoma

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'A phase i study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma'. Together they form a unique fingerprint.

Cite this